Patents by Inventor Iñigo Tirapu Fernandez de la Cuesta

Iñigo Tirapu Fernandez de la Cuesta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATIONS OF LSD1 INHIBITORS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES
    Publication number: 20220331265
    Abstract: The instant invention relates to combinations of the compound of formula (I) or pharmaceutically acceptable salts thereof with other active pharmaceutical ingredients (I), pharmaceutical compositions comprising them, and their use as medicaments, particularly for the treatment of hematological malignancies.
    Type: Application
    Filed: November 19, 2021
    Publication date: October 20, 2022
    Inventors: Filippo CICERI, Serena LUNARDI, Tamara MAES, Cristina MASCARO CRUSAT, Inigo TIRAPU FERNANDEZ DE LA CUESTA
  • Combinations of LSD1 inhibitors for the treatment of hematological malignancies
    Patent number: 11013698
    Abstract: The instant invention relates to combinations of the compound of formula (I) or pharmaceutically acceptable salts thereof with other active pharmaceutical ingredients pharmaceutical compositions comprising them, and their use as medicaments, particularly for the treatment of hematological malignancies.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: May 25, 2021
    Assignee: Oryzon Genomics S.A.
    Inventors: Filippo Ciceri, Serena Lunardi, Tamara Maes, Cristina Mascaro Crusat, Inigo Tirapu Fernandez De La Cuesta
  • Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
    Patent number: 10233178
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: March 19, 2019
    Assignee: Oryzon Genomics, S.A.
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Iñigo Tirapu Fernandez De La Cuesta, Maria de los Ángeles Estiarte Martinez
  • ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE
    Publication number: 20180127406
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Application
    Filed: June 15, 2017
    Publication date: May 10, 2018
    Inventors: Alberto ORTEGA MUÑOZ, Matthew Colin Thor FYEE, Marc MARTINELL PEDEMONTE, Iñigo TIRAPU FERNANDEZ DE LA CUESTA, Maria de los Ángeles ESTIARTE MARTINEZ
  • COMBINATIONS OF LSD1 INHIBITORS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES
    Publication number: 20170281566
    Abstract: The instant invention relates to combinations of the compound of formula (I) or pharmaceutically acceptable salts thereof with other active pharmaceutical ingredients pharmaceutical compositions comprising them, and their use as medicaments, particularly for the treatment of hematological malignancies.
    Type: Application
    Filed: June 23, 2017
    Publication date: October 5, 2017
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Filippo CICERI, Serena LUNARDI, Tamara MAES, Cristina MASCARÓ CRUSAT, Iñigo TIRAPU FERNÁNDEZ DE LA CUESTA
  • LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE OR LYMPHOPROLIFERATIVE DISEASES OR DISORDERS
    Publication number: 20170209432
    Abstract: The present invention relates to methods and compositions for the treatment or prevention of diseases and disorder associated with myeloproliferative and lymphoproliferative disorders. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing diseases and disorder associated with myeloproliferative and lymphoproliferative disorders.
    Type: Application
    Filed: December 5, 2016
    Publication date: July 27, 2017
    Inventors: Matthew Colin Thor FYFE, Tamara MAES, Marc MARTINELL PEDEMONTE, Inigo TIRAPU FERNANDEZ DE LA CUESTA
  • Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
    Patent number: 9708309
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: July 18, 2017
    Assignee: ORYZON GENOMICS, S.A.
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Iñigo Tirapu Fernandez De La Cuesta, Maria de los Ángeles Estiarte-Martinez
  • ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE
    Publication number: 20150376177
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Application
    Filed: September 9, 2015
    Publication date: December 31, 2015
    Inventors: Alberto ORTEGA MUÑOZ, Matthew Colin Thor FYFE, Marc MARTINELL PEDEMONTE, Iñigo TIRAPU FERNANDEZ DE LA CUESTA, Maria de los Ángeles ESTIARTE-MARTINEZ
  • Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
    Patent number: 9181198
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: November 10, 2015
    Assignee: Oryzon Genomics S.A.
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Iñigo Tirapu Fernandez de la Cuesta, Maria de los Ángeles Estiarte-Martínez
  • ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE
    Publication number: 20130231342
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Application
    Filed: July 27, 2011
    Publication date: September 5, 2013
    Applicant: Oryzon Fenomics S.A.
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Iñigo Tirapu Fernandez de la Cuesta, Maria de los Ángeles Estirate-Martinez